Introduction
In May of 2002, the first of a series of FDA -industry workshops on pharmacogenomics was held with the intent to assess the use and status of pharmacogenomic research in drug development. 1 To facilitate communication between FDA and industry regarding appropriate applications of pharmacogenomic data, the FDA proposed that industry submit pharmacogenomic data to the Agency under a concept that was termed 'Safe Harbor'. As the title suggests, the idea was to create a submission process that would provide (1) an exempt status for exploratory pharmacogenomic information so that it would not compromise regular IND, NDA, or BLA submissions, and (2) a platform for an open, scientifically driven information exchange between the Agency and industry. Under this proposal, industry and FDA could explore the use and value of this type of data in drug development outside the usual formal regulatory environment. The need for both was acknowledged at this workshop.
The result of the meeting was a clear directive for FDA to create a guidance document that would help to clarify what type of information would fall within this 'Safe Harbor' process and to clarify how the Agency would review such data outside the usual regulatory process. An important caveat was the recognition that this voluntary process supplemented but did not replace standard regulatory requirements currently in place for new drug submissions. Proceedings of this workshop have been published 2 and the workbook is available online. 1 In November 2003, the FDA released the draft 'Guidance for Industry: Pharmacogenomic Data Submissions', 3 which was immediately followed by a second FDA -Industry workshop on pharmacogenomics. The goal of the guidance was to clarify what type of pharmacogenomic information needs to be submitted to the Agency under existing mandatory regulations and when and how to submit. The guidance also introduced a novel, voluntary submission process for pharmacogenomic data, called the voluntary genomic data submission (VGDS). 4 Even though the term 'Safe Harbor' was discarded, the process that was created provides a 'Regulatory Exempt Environment' for the submission of exploratory genomic data and information. The intent of this voluntary process was to provide a mechanism for FDA to evaluate information outside its usual regulatory decision-making process. To reinforce the integrity of this newly created regulatory exempt environment for VGDS submissions and to maintain distance from the more established and required regulatory routes, the guidance introduced a new FDA-wide review group called the Interdisciplinary Pharmacogenomic Review Group (IPRG), 5 charged with review of these voluntary submissions. Members of the IPRG are comprised of individuals from all centers within the FDA with expertise in pharmacogenomics.
The November 2003 workshop provided the first opportunity for industry to react to this proposal and the response was positive but cautious. For example, the introduction of a classification system for genomic biomarkers (exploratory, probable valid and known valid biomarkers), a critical determinant for distinguishing between voluntary and mandatory data requirements, was controversial and required clarification. Not surprisingly, much of the discussion at the workshop involved clarifying. Proceedings of this workshop have been published 3 with separate publications summarizing the more specific aspects of the individual break-out sessions. [6] [7] [8] On the basis of the information obtained from these two workshops and the feedback that follow publication of the draft guidance, the FDA released the final 'Guidance for Industry: Pharmacogenomic Data Submissions' in March of 2005, a third FDA -Industry workshop was held in April 2005 in Bethesda, Maryland.
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Following a general discussion of topics related to critical aspects of the integration of pharmacogenomics in drug development, a break-out session was held entitled 'Experience with VGDS and Required PG Submissions: From Lessons Learned, How Can Industry and FDA Jointly Improve the Quality of Submissions and Communication About Them?', which is summarized here.
As the title suggested, by the time of the meeting, the FDA had already conducted VGDS reviews of both voluntary and required submissions. The required submissions had followed the well-established patterns of the FDA regulatory process. The voluntary submissions tended to be more experimental in both format and substance. However, early experiences were generally positive and perceived by both FDA and participating sponsors as worthwhile. These experiences provided incentive to both parties to look for mechanisms to work to the development of FDA regulatory policy.
Early work on voluntary submissions demonstrated differences in quality of the submissions between sponsors and also highlighted the need to maintain clear and consistent communication between the participating parties. FDA published a 'Best Practices' guideline for sponsors of voluntary genomic data submissions in order to address both the issues of quality and communication for these submissions.
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There are generally three stages when submitting data to the FDA: presubmission, submission, and postsubmission. At each stage, clear communication helps facilitate the interaction between sponsor and agency and can define the expectations of sponsor and agency. Presubmission conversation can help to clarify the type and format of data submission and define the goals of the submission for both sponsor and agency. Conversations or meetings after submission and review by the FDA are designed to discuss the science and follow-up, as well as answer questions from both groups. Postsubmission exchanges can include additional data and information transfer for further data evaluations, but also serve as a vehicle for feedback. As submissions can be fielded at different stages in drug development and clinical testing, marked differences between the data submitted, the goals of the sponsors, and learning objectives exist.
Track 1 goals
Voluntary as well as required genomic submissions that the FDA receives vary significantly in terms of data quantity and quality. The guidance on Pharmacogenomic Data Submissions outlines what type of data the FDA would like to see, and how to submit it. This track was designed to address the issues of what data quality for genomic data submissions means, how it can be assessed (i.e. data standards), what type of data should be submitted to the FDA (i.e. raw data vs processed data), the timing of submissions and how the interaction between sponsors and the agency can be improved. Three case studies were represented to demonstrate the diversity of VGDS submissions. The subsequent discussions addressed the sponsor -agency interaction at the three stages (presubmission, submission, postsubmission) with the goal of identifying tools for better communication (e.g. a pre-VGDS meeting to discuss planned submissions) as well as identifying specific quality requirements at each of the stages for enhancing the value of VGDS for both sponsor and agency.
At each of the three stages of VGDS interactions, presubmission, submission, postsubmission, the panel and audience provided examples of how clear communication helps facilitate the interaction between sponsor and agency and can define the expectations of sponsor and agency. A dialog occurred on: (1) presubmission conversation that helps to clarify the type and format of data submission and to define the goals of the submission for both sponsor and agency; (2) how discussions or meetings after submission and review by the FDA are designed to discuss the science and follow-up as well as answer questions from both groups; (3) how postsubmission exchanges can include additional data and information transfer for further data evaluations, but also serve as a vehicle for feedback.
Voluntary genomic data submissions can occur at different stages in drug development and clinical testing, which can influence the data submitted, goals of the sponsor and learning experience of the agency. This track discussed the issues of what data quality for genomic data submissions means, how it can be assessed (i.e. data standards), what type of data should be submitted to the FDA (i.e. raw data vs Experience with voluntary and required genomic data submissions to the FDA FW Frueh et al processed data), the timing of submissions and how the interaction between sponsors and the agency can be improved.
In order to present and facilitate the discussion of issues encountered during the review of the first genomic data submissions evaluated by the IPRG, a case study was created that, although hypothetical, closely resembled and included aspects of several actual submissions. The case study described a hypothetical submission with increasing levels of complexity and served to illustrate the sponsor -agency interactions at the three stages (presubmission, submission, postsubmission) of a data submission. The goal was to identify tools and processes for better communication as well as to identify specific quality requirements at each of the stages for enhancing the value of the VGDS process for both sponsor and agency.
Foundation of the hypothetical case study
A vaccine is being developed for a serious infectious disease. Individuals were vaccinated with a peptide derived from a component of the microorganism's outer membrane. Transcriptional profiling interrogating the levels of over 22 000 sequences was performed on peripheral blood mononuclear cells (PBMCs) as an exploratory pharmacogenomics study. Peripheral blood mononuclear cells were collected for analysis at baseline before the first immunization. The goal of the transcriptional profiling study was to discover a preimmunization expression pattern predictive of an immune response to the vaccine and/or able to identify patients at risk of adverse events.
Scenario 1
The VGDS submission contains a review of the concept for an exploratory screen of RNA profiles for pattern discovery in peripheral blood. A description of the clinical protocol, transcriptional profiling methods and proposed statistical analyses is included in the submission. Expression patterns associated with clinical response endpoints will be explored. No data are submitted. 
Scenario 3
The VGDS submission included the same information as scenario 2, except that functional annotation of the genes revealed mechanistic associations with Ig responsiveness or Guillain-Barre Syndrome based on immunological pathways and activated T-and B-cell genes such that the patterns have some biological validation. In addition, the number of patients in the clinical trial was large enough such that the predictive patterns are based on training and test sets. As a result, the sponsor is proposing to move into another clinical trial using the predictive expression patterns to stratify patients for efficacy and risk of Guillain-Barre Syndrome. The goal would be to exclude at-risk patients and eventually apply to the general population to support registration using a companion diagnostic.
Discussion questions for scenario 3
1. What type of data sets should the sponsor submit for the evaluated genes (raw, adjusted, other)? Is a complete set of all data or a partial set requested or required? 2. Will FDA perform its own data analysis with submitted data? 3. What are the advantages and disadvantages of providing complete gene data sets from the perspective of industry and FDA? 4. If a set of expression markers for Guillain-Barre Syndrome susceptibility during vaccination eventually becomes 'validated', will an evaluation of these markers then be expected by FDA for all future vaccine studies? 5. Should the submission include a plan for development of a companion diagnostic derived from these data?
Discussion

Communication
Discussion surrounding early experiences with VGDS highlighted areas of communication between industry and FDA that need improvement. It was generally acknowledged that the expectations of industry and FDA should be defined before submitting a VGDS. To achieve this, early and frequent communication with IPRG was recommended. The submission and review of genomic data does not require new processes (apart from the newly created voluntary submission pathway), but falls within existing regulations.
Value
The value of the opportunity for an informal and interactive dialog was discussed. Such dialog can help sponsors to discuss the context of a submission, explore novel experimental and analysis methods, receive valuable feedback from different disciplinary groups and evaluate statistical analysis plans. Although many of these goals can be accomplished during VGDS meetings, it was emphasized that the meeting time can be too short for a detailed evaluation and presentation of the data. However, FDA recently initiated two-part meetings: an introductory 2 h for the discussion of the clinical aspects of the submitted study and a follow-up 2 h for more in-depth analysis of the data. Although many company representatives saw and acknowledged the value of the VGDS to the sponsor (as well as to the FDA), some commented that without complete protection of their data, they did not see an incentive to participate in the VGDS process. A minority suggested that FDA provide incentives to participate in the VGDS program.
Submissions without data
Early in the VGDS process, the IPRG accepted submissions with limited or no data. Although FDA is still open to discussing such submissions, the value of these submissions and the discussion they provide are compromised by the absence of actual results and an interactive discussion of their interpretation. Consequently, FDA is discouraging this approach and prefers to review submissions containing data, which prove to be more valuable for both FDA and participating sponsors.
Voluntary genomic data submission data sharing Although all VGDS data are handled confidentially, it is also important to note that a mechanism has been set up allowing VGDS data to be evaluated independently from the review of required submissions with which a VGDS may be associated, such as an IND. Even though the issue of access to VGDS data by review divisions was specifically indicated as of great concern to industry as indicated in the comments to the docket of the draft 'Guidance for Industry: Pharmacogenomic Data Submissions', so far, all but one sponsor of a VGDS has requested inclusion of the Clinical Review Division for the product under consideration in the IPRG meeting. It is therefore evident that both sponsors and FDA see the benefit of an open scientific dialog that includes members of the appropriate Review Division in addition to the members of the IPRG.
To comply with confidentiality but nevertheless be able to disseminate the experience and insights derived from the review of VGDS data, the format and general principles such as the approaches to validate biomarkers and statistical issues are shared within the FDA as well as with sponsors.
Data submission and analysis
Genomic data are complex and can entail very large data sets. The submission of genomic data to the FDA requires a mechanism and infrastructure at the Agency to deal with such complex information. FDA has worked diligently to create this infrastructure and the receipt and processing of genomic data are no longer a problem. However, in moving towards a more automated and electronic submission process, many aspects of data handling and storage need to be standardized. Although these procedures are not yet in place, FDA has actively promoted and participated in the development of standards such as HL-7 and CDISC. It is reasonable to anticipate that over the next 2-5 years standards and procedures will be available that allow a fully automated process by which genomic data can be submitted to the FDA.
Today, the IPRG has undertaken the first steps to evaluate large sets of raw hybridization data and gene expression data. Success has been achieved as illustrated in a number of highly effective VGDS meetings regarding such data. However, tighter integration of data analysis tools with standards and formats to facilitate the submission and archiving of genomic data is needed.
Transparency and open communication are important for sponsors to understand what FDA is doing with their data.
This includes information on what tools and methods are used for data evaluation and what databases are used for data interpretation. The IPRG will share this information, as well as the specific results derived from the analysis of actual submissions with the sponsors in detailed reports that include information about the analytical tools that were used. The VGDS process is the ideal platform for this discussion and allows the exchange of experience using different approaches and tools.
Data management
Voluntary submissions are being sent to the Central Document Room with a cover-sheet that clearly indicates the submission as a VGDS (see guidance, ref). Each VGDS is then assigned an IND number if the submission is not already associated with an existing IND. From there, the submission is routed to the IPRG via the Executive Secretary of the IPRG. The data themselves are password-protected and kept on a server accessible only to members of the IPRG. The question of whether safety data should be handled differently from efficacy data was discussed. Although both types of information are considered confidential, it should be noted that, should the Agency become aware of a safety issue based on data submitted under the VGDS pathway, the sponsor will be notified and a solution to the safety issue sought. Both types of data can be submitted via the VGDS pathway unless, as detailed in the pharmacogenomics guidance, the submission becomes required.
Issues surrounding voluntary genomic data submission data
The question was raised as to how FDA will handle observations it is able to derive from the evaluation of data submitted by different sponsors. First and foremost, any data that are submitted as a VGDS is treated as confidential and access to the data is restricted to members of the IPRG only. However, since reviewers utilize their previous experience with other submissions to formulate their insights and comments, it is inevitable that information will be shared between sponsors, although confidentially is still maintained. This is no different than the current review procedures followed by FDA and is a potential benefit of the VGDS process. FDA is in a unique position to review a large number and variety of privately held data, which can help guide industry in the practical application of pharmacogenomics. This insight also illustrates why some sponsors seek early and frequent interaction with the Agency in order to help with strategic decisions on the course of a specific pharmacogenomic development program. In addition, statistical data mining and insights provided by FDA may be useful to sponsors by identifying alternative analytical methodologies and leading to information that is widely applicable. Broad dissemination of this information and insights through publication would greatly enhance the joint learning and improvement process envisioned by the VGDS process.
Drug/test codevelopment A separate track was dedicated to drug-test co-development and therefore the discussion in Track 1 did not go into great detail on this subject. Nevertheless, some critical aspects were discussed. For example, the question about whether or not other sponsors will be required to use a diagnostic if FDA finds the use of it applicable across programs was raised. It was noted that this would depend on the clinical utility of the test and its impact on the safety and efficacy of the drug. Particularly relevant to voluntary submissions was the question as to whether plans for a codeveloped diagnostic should be submitted as a VGDS. This was considered casespecific but of potential benefit to sponsors. Consequently, sponsors were encouraged to engage in presubmission dialog with FDA to help determine the best mechanism for what regulatory tool would best meet company needs for getting feedback from the FDA: a VGDS, a pre-IDE meeting with the Office of In Vitro Diagnostics (OIVD) in the Center for Devices and Radiological Health (CDRH) and/or an endof-phase 2a meeting (Office of Clinical Pharmacology in CDER).
Summary
The VGDS process has become a reality. Benefits to both sponsor and FDA have been identified. However, important issues that will improve the quality and value of submissions remain to be addressed. Increased interactions between sponsor and FDA through VGDS will help guide the application of pharmacogenomics in the pharmaceutical and regulatory settings.
